Clinical trial
Phase II Study of Concurrent C225, Cisplatin and Radiation in Stage IV Squamous…
NCT00096174 · Eastern Cooperative Oncology Group, Other · Completed
Key facts
| NCT number | NCT00096174 |
|---|---|
| Title | Phase II Study of Concurrent C225, Cisplatin and Radiation in Stage IV Squamous Cell Carcinoma of the Head and Neck |
| Official title | Phase II Study of C225 (Erbitux or Cetuximab) in Combination With Cisplatin and Definitive Radiation in Unresectable Stage IV Squamous Cell Carcinoma of the Head and Neck |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Biological, Drug, Radiation |
| Interventions | cetuximab C225, cisplatin, radiation therapy |
| Enrollment | 69 |
| Start date | Apr 8, 2005 |
| Primary completion | Jul 1, 2009 |
| Completion | Jul 1, 2016 |
| First posted | Nov 9, 2004 |
| Last update posted | Jun 29, 2023 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: